P05231 (IL6_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Names and origin

Protein names

Recommended name:
Interleukin-6
Short name=IL-6

Alternative name(s):
B-cell stimulatory factor 2
Short name=BSF-2
CTL differentiation factor
Short name=CDF
Hybridoma growth factor
Interferon beta-2
Short name=IFN-beta-2

Gene names

Name:	IL6
Synonyms:	IFNB2

Organism

Homo sapiens (Human) [Reference proteome]

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

cellular organisms › Eukaryota › Opisthokonta › Metazoa › Eumetazoa › Bilateria › Deuterostomia › Chordata › Craniata › Vertebrata › Gnathostomata › Teleostomi › Euteleostomi › Sarcopterygii › Tetrapoda › Amniota › Mammalia › Theria › Eutheria › Euarchontoglires › Primates › Haplorrhini › Simiiformes › Catarrhini › Hominoidea › Hominidae › Homininae › Homo

Protein attributes

Sequence length	212 AA.
Sequence status	Complete.
Sequence processing	The displayed sequence is further processed into a mature form.
Protein existence	Evidence at protein level

General annotation (Comments)

Function	Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
Subcellular location	Secreted.
Post-translational modification	N- and O-glycosylated. Ref.14
Polymorphism	Genetic variations in IL6 may be correlated with bone mineral density (BMD). Low BMD is a risk factor for osteoporotic fracture. Osteoporosis is characterized by reduced bone mineral density, disrutption of bone microarchitecture, and the alteration of the amount and variety of non-collagenous proteins in bone. Osteoporotic bones are more at risk of fracture.
Involvement in disease	Rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]: An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
Sequence similarities	Belongs to the IL-6 superfamily.

Ontologies

Keywords
Biological process	Acute phase
Cellular component	Secreted
Coding sequence diversity	Polymorphism
Domain	Signal
Molecular function	Cytokine Growth factor
PTM	Disulfide bond Glycoprotein
Technical term	3D-structure Complete proteome Direct protein sequencing Reference proteome
Gene Ontology (GO)
Biological_process	T cell activation Inferred from electronic annotation. Source: Compara acute-phase response Traceable author statement PubMed 12832423. Source: BHF-UCL aging Inferred from electronic annotation. Source: Compara bone remodeling Inferred from electronic annotation. Source: Compara branching involved in salivary gland morphogenesis Inferred from electronic annotation. Source: Compara cell growth Inferred from electronic annotation. Source: Compara cell redox homeostasis Inferred from electronic annotation. Source: Compara cellular response to hydrogen peroxide Inferred from direct assay PubMed 19168699. Source: BHF-UCL defense response to Gram-negative bacterium Inferred from expression pattern PubMed 16034137. Source: BHF-UCL defense response to Gram-positive bacterium Inferred from expression pattern PubMed 16034137. Source: BHF-UCL defense response to protozoan Inferred from electronic annotation. Source: Compara defense response to virus Inferred from direct assay Ref.4. Source: BHF-UCL endocrine pancreas development Inferred from sequence or structural similarity PubMed 18719127. Source: BHF-UCL epithelial cell proliferation involved in salivary gland morphogenesis Inferred from electronic annotation. Source: Compara glucagon secretion Inferred from sequence or structural similarity PubMed 18719127. Source: BHF-UCL hepatic immune response Inferred from direct assay PubMed 2444978. Source: BHF-UCL humoral immune response Inferred by curator Ref.1. Source: BHF-UCL interleukin-6-mediated signaling pathway Inferred from direct assay PubMed 12552091. Source: BHF-UCL monocyte chemotaxis Inferred by curator PubMed 10510402. Source: BHF-UCL muscle cell homeostasis Inferred from electronic annotation. Source: Compara negative regulation of apoptotic process Inferred from direct assay PubMed 7595060. Source: UniProtKB negative regulation of cell proliferation Traceable author statement Ref.4. Source: ProtInc negative regulation of chemokine biosynthetic process Inferred from sequence or structural similarity. Source: UniProtKB negative regulation of collagen biosynthetic process Inferred from direct assay PubMed 12419823. Source: BHF-UCL negative regulation of cysteine-type endopeptidase activity involved in apoptotic process Inferred from electronic annotation. Source: Compara negative regulation of cytokine secretion Inferred from electronic annotation. Source: Compara negative regulation of fat cell differentiation Non-traceable author statement PubMed 16464856. Source: BHF-UCL negative regulation of gluconeogenesis Inferred from electronic annotation. Source: Compara negative regulation of hormone secretion Inferred from electronic annotation. Source: Compara negative regulation of lipid storage Non-traceable author statement PubMed 16464856. Source: BHF-UCL negative regulation of muscle organ development Inferred from electronic annotation. Source: Compara negative regulation of neuron death Inferred from electronic annotation. Source: Compara negative regulation of protein kinase activity Inferred from electronic annotation. Source: Compara neuron projection development Inferred from mutant phenotype PubMed 3264880. Source: BHF-UCL neutrophil apoptotic process Inferred from direct assay PubMed 7595060. Source: UniProtKB neutrophil mediated immunity Inferred by curator PubMed 16034137. Source: BHF-UCL platelet activation Traceable author statement PubMed 7831669. Source: BHF-UCL positive regulation of B cell activation Inferred from direct assay Ref.1. Source: BHF-UCL positive regulation of DNA replication Inferred from electronic annotation. Source: Compara positive regulation of ERK1 and ERK2 cascade Inferred from electronic annotation. Source: Compara positive regulation of MAPK cascade Inferred from direct assay PubMed 12419823. Source: BHF-UCL positive regulation of STAT protein import into nucleus Inferred by curator PubMed 17324931. Source: BHF-UCL positive regulation of T cell proliferation Inferred from direct assay PubMed 3130269. Source: BHF-UCL positive regulation of T-helper 2 cell differentiation Inferred from electronic annotation. Source: Compara positive regulation of acute inflammatory response Inferred from direct assay PubMed 2444978. Source: BHF-UCL positive regulation of chemokine production Inferred from direct assay PubMed 10510402. Source: BHF-UCL positive regulation of epithelial cell proliferation Inferred from electronic annotation. Source: Compara positive regulation of immunoglobulin secretion Inferred from direct assay Ref.1. Source: BHF-UCL positive regulation of interleukin-6 production Inferred from direct assay PubMed 10510402. Source: BHF-UCL positive regulation of leukocyte chemotaxis Inferred by curator PubMed 16034137. Source: BHF-UCL positive regulation of neuron differentiation Inferred from electronic annotation. Source: Compara positive regulation of nitric oxide biosynthetic process Inferred from electronic annotation. Source: Compara positive regulation of osteoblast differentiation Traceable author statement PubMed 12372336. Source: BHF-UCL positive regulation of peptidyl-serine phosphorylation Inferred from direct assay PubMed 7508917. Source: MGI positive regulation of protein import into nucleus, translocation Inferred from electronic annotation. Source: Compara positive regulation of protein kinase B signaling cascade Inferred from electronic annotation. Source: Compara positive regulation of sequence-specific DNA binding transcription factor activity Inferred from direct assay PubMed 7749983. Source: BHF-UCL positive regulation of smooth muscle cell proliferation Inferred from direct assay PubMed 10510402. Source: BHF-UCL positive regulation of transcription from RNA polymerase II promoter Inferred from direct assay PubMed 17324931. Source: BHF-UCL positive regulation of translation Inferred from direct assay PubMed 16732314. Source: UniProtKB positive regulation of transmission of nerve impulse Inferred from electronic annotation. Source: Compara positive regulation of tyrosine phosphorylation of Stat3 protein Inferred from direct assay PubMed 12643274. Source: BHF-UCL regulation of angiogenesis Inferred by curator PubMed 8557680. Source: BHF-UCL regulation of cell shape Inferred from electronic annotation. Source: Compara regulation of circadian sleep/wake cycle, non-REM sleep Inferred from electronic annotation. Source: Compara regulation of vascular endothelial growth factor production Inferred from direct assay PubMed 8557680. Source: BHF-UCL response to amino acid stimulus Inferred from electronic annotation. Source: Compara response to antibiotic Inferred from electronic annotation. Source: Compara response to caffeine Inferred from electronic annotation. Source: Compara response to calcium ion Inferred from electronic annotation. Source: Compara response to cold Inferred from electronic annotation. Source: Compara response to drug Inferred from electronic annotation. Source: Compara response to electrical stimulus Inferred from electronic annotation. Source: Compara response to glucocorticoid stimulus Inferred from direct assay PubMed 10443688. Source: BHF-UCL response to heat Inferred from electronic annotation. Source: Compara response to insulin stimulus Inferred from electronic annotation. Source: Compara response to lipopolysaccharide Inferred from electronic annotation. Source: Compara response to mechanical stimulus Inferred from electronic annotation. Source: Compara response to nutrient levels Inferred from electronic annotation. Source: Compara response to peptidoglycan Inferred from expression pattern PubMed 16034137. Source: BHF-UCL
Cellular_component	external side of plasma membrane Inferred from electronic annotation. Source: Compara extracellular space Inferred from direct assay PubMed 10443688PubMed 16034137Ref.4. Source: BHF-UCL interleukin-6 receptor complex Inferred from direct assay PubMed 12829785PubMed 2261637. Source: BHF-UCL
Molecular_function	cytokine activity Inferred from direct assay Ref.4Ref.1. Source: BHF-UCL growth factor activity Inferred from direct assay PubMed 12643274PubMed 2261637. Source: BHF-UCL interleukin-6 receptor binding Non-traceable author statement Ref.14. Source: UniProtKB
Complete GO annotation...

Sequence annotation (Features)

Feature key

Position(s)

Length

Description

Graphical view

Feature identifier

Molecule processing

Signal peptide

1 – 29

29

Ref.12 Ref.13 Ref.14

Chain

30 – 212

183

Interleukin-6

PRO_0000015582

Amino acid modifications

Glycosylation

73

1

N-linked (GlcNAc...)

Disulfide bond

72 ↔ 78

Ref.15 Ref.16

Disulfide bond

101 ↔ 111

Ref.15 Ref.16

Natural variations

Natural variant

32

1

P → S. Ref.10
Corresponds to variant rs2069830 [ dbSNP | Ensembl ].

VAR_013075

Natural variant

162

1

D → E.
Corresponds to variant rs13306435 [ dbSNP | Ensembl ].

VAR_029266

Natural variant

162

1

D → V. Ref.10
Corresponds to variant rs2069860 [ dbSNP | Ensembl ].

VAR_013076

Experimental info

Mutagenesis

173

1

A → V: Almost no loss of activity.

Mutagenesis

185

1

W → R: No loss of activity.

Mutagenesis

204

1

S → P: 87% loss of activity.

Mutagenesis

210

1

R → K, E, Q, T, A or P: Loss of activity.

Mutagenesis

212

1

M → T, N, S or R: Loss of activity.

Secondary structure

1

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

212

Helix Strand Turn

Details...

Helix

49 – 75

27

Beta strand

76 – 82

7

Helix

97 – 99

3

Beta strand

102 – 105

4

Helix

108 – 132

25

Beta strand

134 – 136

3

Helix

137 – 157

21

Beta strand

159 – 161

3

Helix

169 – 180

12

Helix

184 – 209

26

Sequences

	Sequence		Length	Mass (Da)
	P05231 [UniParc]. Last modified August 13, 1987. Version 1. Checksum: 1F1ED1FE1B734079	FASTA	212	23,718
	10 20 30 40 50 60 MNSFSTSAFG PVAFSLGLLL VLPAAFPAPV PPGEDSKDVA APHRQPLTSS ERIDKQIRYI 70 80 90 100 110 120 LDGISALRKE TCNKSNMCES SKEALAENNL NLPKMAEKDG CFQSGFNEET CLVKIITGLL 130 140 150 160 170 180 EFEVYLEYLQ NRFESSEEQA RAVQMSTKVL IQFLQKKAKN LDAITTPDPT TNASLLTKLQ 190 200 210 AQNQWLQDMT THLILRSFKE FLQSSLRALR QM

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin." Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T. Nature 324:73-76(1986) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE.
[2]	"Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene." Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T., Nakai S., Kishimoto T. EMBO J. 6:2939-2945(1987) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA].
[3]	"Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved." May L.T., Helfgott D.C., Sehgal P.B. Proc. Natl. Acad. Sci. U.S.A. 83:8957-8961(1986) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[4]	"Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines." Zilberstein A., Ruggieri R., Korn J.H., Revel M. EMBO J. 5:2529-2537(1986) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[5]	"Molecular cloning and expression of hybridoma growth factor in Escherichia coli." Brakenhoff J.P.J., de Groot E.R., Evers R.F., Pannekoek H., Aarden L.A. J. Immunol. 139:4116-4121(1987) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[6]	"Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells." Tonouchi N., Miwa K., Karasuyama H., Matsui H. Biochem. Biophys. Res. Commun. 163:1056-1062(1989) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[7]	"Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts." Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J., Fiers W. Eur. J. Biochem. 159:625-632(1986) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]. Tissue: Fibroblast.
[8]	"Interleukin 6: identification as a hematopoietic colony-stimulating factor." Wong G., Witek-Giannotti J., Hewick R., Clark S., Ogawa M. Behring Inst. Mitt. 83:40-47(1988) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[9]	"Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer." Chen Q.Y. Zhonghua Zhong Liu Za Zhi 14:340-344(1992) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA].
[10]	SeattleSNPs variation discovery resource Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS SER-32 AND VAL-162.
[11]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Lung.
[12]	"Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6." van Damme J., van Beeumen J., Decock B., van Snick J., de Ley M., Billiau A. J. Immunol. 140:1534-1541(1988) [PubMed] [Europe PMC] [Abstract] Cited for: PROTEIN SEQUENCE OF 30-63.
[13]	"Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium." Ming J.E., Cernetti C., Steinman R.M., Granelli-Piperno A. J. Mol. Cell. Immunol. 4:203-211(1989) [PubMed] [Europe PMC] [Abstract] Cited for: PROTEIN SEQUENCE OF 30-50.
[14]	"Marked cell-type-specific differences in glycosylation of human interleukin-6." May L.T., Shaw J.E., Khanna A.K., Zabriskie J.B., Sehgal P.B. Cytokine 3:204-211(1991) [PubMed] [Europe PMC] [Abstract] Cited for: PROTEIN SEQUENCE OF 30-40, GLYCOSYLATION.
[15]	"Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond." Breton J., la Fiura A., Bertolero F., Orsini G., Valsasina B., Ziliotto R., de Filippis V., Polverino de Laureto P., Fontana A. Eur. J. Biochem. 227:573-581(1995) [PubMed] [Europe PMC] [Abstract] Cited for: PROTEIN SEQUENCE OF 50-212 OF RECOMBINANT FORM LACKING FIRST DISULFIDE BOND.
[16]	"Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor." Clogston C.L., Boone T.C., Crandall B.C., Mendiaz E.A., Lu H.S. Arch. Biochem. Biophys. 272:144-151(1989) [PubMed] [Europe PMC] [Abstract] Cited for: DISULFIDE BONDS.
[17]	"Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6." Luetticken C., Kruettgen A., Moeller C., Heinrich P.C., Rose-John S. FEBS Lett. 282:265-267(1991) [PubMed] [Europe PMC] [Abstract] Cited for: MUTAGENESIS.
[18]	"Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy." Nishimura C., Watanabe A., Gouda H., Shimada I., Arata Y. Biochemistry 35:273-281(1996) [PubMed] [Europe PMC] [Abstract] Cited for: STRUCTURE BY NMR.
[19]	"Solution structure of recombinant human interleukin-6." Xu G.-Y., Yu H.-A., Hong J., Stahl M., McDonagh T., Kay L.E., Cumming D.A. J. Mol. Biol. 268:468-481(1997) [PubMed] [Europe PMC] [Abstract] Cited for: STRUCTURE BY NMR.
[20]	"1.9-A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling." Somers W., Stahl M., Seehra J.S. EMBO J. 16:989-997(1997) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
[21]	"The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis." Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. J. Clin. Invest. 102:1369-1376(1998) [PubMed] [Europe PMC] [Abstract] Cited for: INVOLVEMENT IN SUSCEPTIBILITY TO SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS.
[22]	"An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus." Foster C.B., Lehrnbecher T., Samuels S., Stein S., Mol F., Metcalf J.A., Wyvill K., Steinberg S.M., Kovacs J., Blauvelt A., Yarchoan R., Chanock S.J. Blood 96:2562-2567(2000) [PubMed] [Europe PMC] [Abstract] Cited for: INVOLVEMENT IN SUSCEPTIBILITY TO KAPOSI SARCOMA.
[23]	"A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density." Ota N., Nakajima T., Nakazawa I., Suzuki T., Hosoi T., Orimo H., Inoue S., Shirai Y., Emi M. J. Hum. Genet. 46:267-272(2001) [PubMed] [Europe PMC] [Abstract] Cited for: INVOLVEMENT IN BMD.
[24]	"Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women." Chung H.W., Seo J.-S., Hur S.E., Kim H.L., Kim J.Y., Jung J.H., Kim L.H., Park B.L., Shin H.D. J. Hum. Genet. 48:243-248(2003) [PubMed] [Europe PMC] [Abstract] Cited for: INVOLVEMENT IN BMD.
+	Additional computationally mapped references.

Web resources

R&D Systems' cytokine mini-reviews: IL-6

Wikipedia

Interleukin-6 entry

SeattleSNPs

SHMPD

The Singapore human mutation and polymorphism database

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Cross-references

Sequence databases

EMBL
GenBank
DDBJ

X04430 mRNA. Translation: CAA28026.1.
M14584 mRNA. Translation: AAA52728.1.
X04602 mRNA. Translation: CAA28268.1.
Y00081 Genomic DNA. Translation: CAA68278.1.
M18403 mRNA. Translation: AAA52729.1.
M29150 mRNA. Translation: AAA59154.1.
X04402 Genomic DNA. Translation: CAA27990.1.
X04403 mRNA. Translation: CAA27991.1.
M54894 mRNA. Translation: AAC41704.1.
S56892 mRNA. Translation: AAD13886.1.
AF372214 Genomic DNA. Translation: AAK48987.1.
BC015511 mRNA. Translation: AAH15511.1.

IPI

IPI00007793.

PIR

IVHUB2. A32648.

RefSeq

NP_000591.1. NM_000600.3.

UniGene

Hs.654458.

3D structure databases

PDBe
RCSB PDB
PDBj

Entry	Method	Resolution (Å)	Chain	Positions	PDBsum
1ALU	X-ray	1.90	A	28-212	[»]
1IL6	NMR	-	A	28-212	[»]
1N2Q	model	-	E/F	30-212	[»]
1P9M	X-ray	3.65	B	29-212	[»]
2IL6	NMR	-	A	28-212	[»]

ProteinModelPortal

P05231.

ModBase

Search...

Protein-protein interaction databases

DIP

DIP-482N.

IntAct

P05231. 4 interactions.

MINT

MINT-190042.

STRING

9606.ENSP00000258743.

PTM databases

PhosphoSite

P05231.

Polymorphism databases

DMDM

124347.

Proteomic databases

PaxDb

P05231.

PRIDE

P05231.

Protocols and materials databases

DNASU

3569.

StructuralBiologyKnowledgebase

Search...

Genome annotation databases

Ensembl

ENST00000258743; ENSP00000258743; ENSG00000136244.
ENST00000404625; ENSP00000385675; ENSG00000136244.

GeneID

3569.

KEGG

hsa:3569.

UCSC

uc003svj.4. human.

Organism-specific databases

CTD

3569.

GeneCards

GC07P022732.

H-InvDB

HIX0167872.

HGNC

HGNC:6018. IL6.

HPA

CAB023406.

MIM

147620. gene.
148000. phenotype.
604302. phenotype.

neXtProt

NX_P05231.

Orphanet

206. Crohn disease.
85414. Systemic-onset juvenile idiopathic arthritis.

PharmGKB

PA198.

GenAtlas

Search...

Phylogenomic databases

eggNOG

NOG48083.

HOGENOM

HOG000236330.

HOVERGEN

HBG000471.

InParanoid

P05231.

KO

K05405.

OMA

LQFSLRA.

OrthoDB

EOG44J2KH.

PhylomeDB

P05231.

Enzyme and pathway databases

Pathway_Interaction_DB

amb2_neutrophils_pathway. amb2 Integrin signaling.
faspathway. FAS signaling pathway (CD95).
il23pathway. IL23-mediated signaling events.
il27pathway. IL27-mediated signaling events.
il6_7pathway. IL6-mediated signaling events.
lysophospholipid_pathway. LPA receptor mediated events.

Reactome

REACT_6900. Immune System.

Gene expression databases

ArrayExpress

P05231.

Bgee

P05231.

CleanEx

HS_IL6.

Genevestigator

P05231.

GermOnline

ENSG00000136244. Homo sapiens.

Family and domain databases

Gene3D

1.20.1250.10. 1 hit.

InterPro

IPR009079. 4_helix_cytokine-like_core.
IPR012351. 4_helix_cytokine_core.
IPR003573. IL6_MGF_GCSF.
IPR003574. Interleukin_6.
[Graphical view]

PANTHER

PTHR11457. PTHR11457. 1 hit.

Pfam

PF00489. IL6. 1 hit.
[Graphical view]

PIRSF

PIRSF001935. IL6_MGF_GCSF. 1 hit.

PRINTS

PR00433. IL6GCSFMGF.
PR00434. INTERLEUKIN6.

SMART

SM00126. IL6. 1 hit.
[Graphical view]

SUPFAM

SSF47266. 4_helix_cytokine. 1 hit.

PROSITE

PS00254. INTERLEUKIN_6. 1 hit.
[Graphical view]

ProtoNet

Search...

Other

ChEMBL

CHEMBL1795129.

ChiTaRS

IL6. human.

DrugBank

DB01169. Arsenic trioxide.
DB01128. Bicalutamide.
DB01404. Ginseng.
DB00641. Simvastatin.

EvolutionaryTrace

P05231.

GenomeRNAi

3569.

NextBio

13950.

PMAP-CutDB

P05231.

SOURCE

Search...

Entry information

Entry name

IL6_HUMAN

Accession

Primary (citable) accession number: P05231
Secondary accession number(s): Q9UCU2, Q9UCU3, Q9UCU4

Entry history

Integrated into UniProtKB/Swiss-Prot:	August 13, 1987
Last sequence update:	August 13, 1987
Last modified:	May 1, 2013
This is version 163 of the entry and version 1 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation program

Chordata Protein Annotation Program

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.